Methylophiopogonanone A

Research use only, not for human use.

Methylophiopogonanone A has anti-inflammatory and anti-oxidative properties.

Methylophiopogonanone A has anti-inflammatory and anti-oxidative properties. Methylophiopogonanone A has therapeutic potential against cerebral I/R injury through its ability to attenuate BBB disruption by regulating the expression of MMP-9 and tight junction proteins.

Methylophiopogonanone A (MO-A; 10 μmol/L) significantly decreases apoptosis and cleaved caspase-3 expression, elevated the Bcl-2/Bax ratio and restored NO production. Pretreatment with Methylophiopogonanone A (MO-A) markedly increases the activation of PI3K/Akt/eNOS pathway in H9C2 cells subjected to H/R, and the protective effects of MO-A are abolished in the presence of the PI3K inhibitor wortmannin (100 nmol/L).

Methylophiopogonanone A (MO-A;10 mg/kg/d, po) for 2 weeks) protects cardiac function following myocardial I/R injury.

——

Others

Other Targets

Others

Others-Field

——

74805-92-8

342.34

C19H18O6

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (292.11 mM)

CC1=C(C2=C(C(=C1O)C)OCC(C2=O)CC3=CC4=C(C=C3)OCO4)O

——

(-20℃)

With Ice Pack

≥ 2 years